Skip to main content
. 2022 Jan 25;75(6):975–986. doi: 10.1093/cid/ciac036

Figure 4.

Figure 4.

Summary of adverse events (AEs) after week 48. Abbreviations: DTG/3TC, dolutegravir/lamivudine; TAF, tenofovir alafenamide.